#China #Chongqing #Botulinum Toxin #Claruvis #Retoxin

Claruvis Pharmaceutical's Historic Milestone: Retoxin® Approval in China

Chongqing Claruvis Pharmaceutical Co., Ltd. recently made headlines by achieving a remarkable milestone in the field of biopharmaceuticals. The company’s product, Retoxin®, has been granted market approval by the National Medical Products Administration (NMPA) of China. This approval marks a pivotal moment not only for Claruvis Pharmaceuticals but also for the global pharmaceutical industry as Retoxin® is recognized as the world's first recombinant botulinum toxin type A to gain regulatory approval.

A Technological Revolution in Botulinum Toxin Production

Retoxin® represents a significant deviation from traditional botulinum toxin products that are derived from the natural extraction process of Clostridium botulinum. Claruvis has developed Retoxin® using a revolutionary recombinant technology, which employs precise genetic engineering methods to manufacture the toxin. This novel approach eliminates the biosafety risks associated with traditional production techniques and results in a product that boasts high purity and specific activity.

The company utilized its proprietary recombinant platform and manufacturing system to ensure that the molecular structure of the active protein retains its integral 150-kDa neurotoxin structure. This technical advancement not only enhances the quality of the product but also positions Claruvis at the forefront of biopharmaceutical innovation.

Clinical Study Success and Efficacy

In a pivotal, randomized, double-blind, placebo- and active-controlled Phase III clinical study conducted in China, Retoxin® achieved all primary and secondary endpoints. The results demonstrated its superior effectiveness, favorable safety profile, and low immunogenicity, highlighting the potential benefits of recombinant technology in both aesthetic and therapeutic uses of botulinum neurotoxins.

Claruvis Pharmaceutical is also extending the applications of Retoxin® beyond cosmetic uses. The company is currently developing the product for therapeutic interventions in adults suffering from upper extremity spasticity post-stroke or traumatic brain injuries. After successfully completing a Phase II clinical study, Claruvis is now enrolling patients in a multicenter Phase III study across more than 20 clinical trial sites in China. Their goal is to offer a safer and more effective treatment option for patients dealing with debilitating spasticity.

A Vision for the Future

Dr. Yang, the Chief Scientific Officer at Claruvis Pharmaceutical, expressed that “Retoxin® is a significant commercial milestone for our recombinant platform. It confirms our vision of developing next-generation botulinum neurotoxins with improved purity, consistency, and safety.” The company is dedicated to building a robust pipeline of recombinant products aimed at addressing a wide array of neurological and aesthetic indications.

Mr. Liu, the Chairman and CEO of Claruvis Pharmaceutical, further commented, “This approval in China is an important step forward. We are committed to advancing our innovative portfolio of recombinant botulinum toxins and providing groundbreaking treatment options for patients and physicians worldwide.”

About Claruvis Pharmaceutical

Established as a subsidiary of MingMed Biotechnology, Claruvis Pharmaceutical Co., Ltd. is an innovation-driven biopharmaceutical company. It focuses on the research, development, manufacture, and marketing of recombinant botulinum toxin products. By being the first globally to obtain regulatory approval for a recombinant botulinum toxin type A, Claruvis has not only transformed the traditional methods of natural extraction but also set a new standard of quality and safety in pharmaceuticals aimed at both aesthetic and therapeutic applications.

With this monumental approval, Claruvis Pharmaceutical is poised to lead the charge in the evolution of botulinum neurotoxin therapies, encouraging a new era of treatment options for patients and healthcare providers alike.